Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share

Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.01 million.

For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping withdraws bid to acquire Genco Shipping
• H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)